NIPS

During the first year of the TRIDENT-2 study, 74,000 women opted for NIPT, which was switched from in-house-developed platforms to Illumina's VeriSeq in May of this year.

The report states that using NIPD for trisomy 21 in high-risk women could "probably reduce" the total number of invasive tests though the data is incomplete.

The company plans to launch the system this summer in Europe, aiming to broaden cell-free DNA screening for trisomy 21, 18, and 13.

Noninvasive prenatal screening for trisomies and sub-chromosomal alterations uncovered a fragile site expansion and related deletion present in mothers but not fetuses.

Although other groups have been developing noninvasive prenatal testing using digital PCR, BioCore claims to be the first to offer a test commercially.

Adam Wolfberg argued that while corporate conflicts are widely discussed, physicians also have financial conflicts that can bias them against new technology.

Limited Access

Poor women have limited access to noninvasive prenatal screening tools, a post at Health Affairs' blog says.

The China Food and Drug Administration had also previously accredited both the NIFTY test and the BGISEQ sequencing platform.

Increased consumer interest in prenatal health is also spurring use of carrier screening for genetic conditions.

In a study involving almost 23,000 women, DNA reflex testing detect 95 percent of trisomies while avoiding recalls. 

Pages

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.